Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Microbiota in interstitial cystitis/bladder pain syndrome: evidence and opportunities
David J. Klumpp
David J. Klumpp
View: Text | PDF
Viewpoint

Microbiota in interstitial cystitis/bladder pain syndrome: evidence and opportunities

  • Text
  • PDF
Abstract

Authors

David J. Klumpp

×

Figure 1

Gut microbiota’s influence on IC symptoms and clinical importance.

Options: View larger image (or click on image) Download as PowerPoint
Gut microbiota’s influence on IC symptoms and clinical importance.
(A) V...
(A) Visceral convergence of bladder and gut sensory pathways mediate organ crosstalk and the bladder-gut-brain axis. Gut dysbiosis in IC may directly influence sensory pathways, or microbial constituents (LPS and peptidoglycan [PG]) and metabolites in circulation can influence pain circuits centrally via microglia. (B) Dysbiosis-associated immune dysregulation may impact IC pathology by altering the inflammatory milieu and thus affect bladder mast cells and/or Hunner’s lesions. (C) Microglia are potential therapeutic targets for IC by use of drugs that act directly or indirectly.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts